These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15464070)

  • 21. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats.
    Shimazaki T; Kaku A; Chaki S
    Eur J Pharmacol; 2007 Dec; 575(1-3):94-7. PubMed ID: 17727837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039.
    Yoshimizu T; Chaki S
    Biochem Biophys Res Commun; 2004 Mar; 315(2):493-6. PubMed ID: 14766235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
    Nicolas LB; Kolb Y; Prinssen EP
    Eur J Pharmacol; 2006 Oct; 547(1-3):106-15. PubMed ID: 16934246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.
    Dong C; Zhang JC; Yao W; Ren Q; Ma M; Yang C; Chaki S; Hashimoto K
    Int J Neuropsychopharmacol; 2017 Mar; 20(3):228-236. PubMed ID: 27765808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord.
    Howson PA; Jane DE
    Br J Pharmacol; 2003 May; 139(1):147-55. PubMed ID: 12746233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.
    Spooren WP; Vassout A; Neijt HC; Kuhn R; Gasparini F; Roux S; Porsolt RD; Gentsch C
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1267-75. PubMed ID: 11082464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
    J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
    Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
    J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):546-54. PubMed ID: 11138847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    J Pharmacol Exp Ther; 2001 Aug; 298(2):453-60. PubMed ID: 11454905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of glutamate-related drugs on anxiety and compulsive behavior in rats with obsessive-compulsive disorder.
    Zhan Y; Xia J; Wang X
    Int J Neurosci; 2020 Jun; 130(6):551-560. PubMed ID: 31680595
    [No Abstract]   [Full Text] [Related]  

  • 35. Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats.
    Pilc A; Chojnacka-Wójcik E; Tatarczyńska E; Borycz J; Kroczka B
    Amino Acids; 2000; 19(1):81-6. PubMed ID: 11026476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
    Ornstein PL; Bleisch TJ; Arnold MB; Kennedy JH; Wright RA; Johnson BG; Tizzano JP; Helton DR; Kallman MJ; Schoepp DD; Hérin M
    J Med Chem; 1998 Jan; 41(3):358-78. PubMed ID: 9464367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium-channel antagonists inhibit marble-burying behavior in mice.
    Egashira N; Okuno R; Abe M; Matsushita M; Mishima K; Iwasaki K; Oishi R; Nishimura R; Matsumoto Y; Fujiwara M
    J Pharmacol Sci; 2008 Sep; 108(1):140-3. PubMed ID: 18758134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.
    Woltering TJ; Adam G; Huguenin P; Wichmann J; Kolczewski S; Gatti S; Bourson A; Kew JN; Richards G; Kemp JA; Mutel V; Knoflach F
    ChemMedChem; 2008 Feb; 3(2):323-35. PubMed ID: 18058780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of agents targeting glutamatergic systems on marble-burying behavior.
    Iijima M; Kurosu S; Chaki S
    Neurosci Lett; 2010 Mar; 471(2):63-5. PubMed ID: 20036313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.